Clinical Trial Update: A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 study comparing once-daily dosing of Fuzeon (enfuvirtide) to the standard twice-daily regimen in HIV-1 infected patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Fuzeon (enfuvirtide)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: HIV Infections | Phase 2 | Status: COMPLETED